A Retrospective Review of Tocilizumab for the Management of Blinatumomab (a Bispecific T Cell Engager)-Induced Cytokine Release Syndrome (CRS)

被引：10
|
作者：
Choudhry, Jessica [1 ]
Parson, Mandy [1 ]
Wright, Jacqueline [1 ]
机构：
[1] Amgen Inc, Thousand Oaks, CA 91320 USA
来源：
BLOOD | 2018年 / 132卷
关键词：
D O I：
10.1182/blood-2018-99-117353
中图分类号：
R5 [内科学];
学科分类号：
1002 ; 100201 ;
摘要：
5211
引用
收藏
页数：2
相关论文
共 50 条
  • [1] Dissecting the Mechanisms Underlying the Cytokine Release Syndrome (CRS) Mediated by T-Cell Bispecific Antibodies
    Leclercq-Cohen, Gabrielle
    Steinhoff, Nathalie
    Alberti Servera, Llucia
    Nassiri, Sina
    Danilin, Sabrina
    Piccione, Emily
    Yangueez, Emilio
    Huesser, Tamara
    Herter, Sylvia
    Schmeing, Stephan
    Gerber, Petra
    Schwalie, Petra
    Sam, Johannes
    Briner, Stefanie
    Jenni, Sylvia
    Bianchi, Roberta
    Biehl, Marlene
    Cremasco, Floriana
    Apostolopoulou, Katerina
    Haegel, Helene
    Klein, Christian
    Umana, Pablo
    Bacac, Marina
    CLINICAL CANCER RESEARCH, 2023, 29 (21) : 4449 - 4463
  • [2] The Potential of Bispecific T-Cell Engager (BiTE®) in Cancer: Blinatumomab and More
    Klinger, M.
    ANNALS OF HEMATOLOGY, 2015, 94 (SUPPL 1) : 71 - 72
  • [3] The Potential of Bispecific T-Cell Engager (BiTE®) in Cancer: Blinatumomab and More
    Klinger, M.
    ANNALS OF HEMATOLOGY, 2015, 94 : S71 - S72
  • [4] Tocilizumab Management in the Cytokine Release Syndrome
    Martin Benito, Cristina
    Sanguesa Dominguez, Silvia
    Gonzalez Rodriguez, Maria Cristina
    BONE MARROW TRANSPLANTATION, 2020, 55 (SUPPL 1) : 746 - 746
  • [5] Prophylactic Tocilizumab to Prevent Cytokine Release Syndrome (CRS) with Teclistamab Administration
    Marin, Ellen
    Scott, Sara
    Maples, Kathryn
    Joseph, Nisha S.
    Hofmeister, Craig C.
    Gupta, Vikas A.
    Dhodapkar, Madhav V.
    Kaufman, Jonathan L.
    Lonial, Sagar
    Nooka, Ajay K.
    BLOOD, 2023, 142
  • [6] Tocilizumab for the treatment of chimeric antigen receptor T cell-induced cytokine release syndrome
    Kotch, Chelsea
    Barrett, David
    Teachey, David T.
    EXPERT REVIEW OF CLINICAL IMMUNOLOGY, 2019, 15 (08) : 813 - 822
  • [7] Tocilizumab: The Key to Stop Coronavirus Disease 2019 (COVID-19)-Induced Cytokine Release Syndrome (CRS)?
    Liu, Danfei
    Zhang, Tongyue
    Wang, Yijun
    Xia, Limin
    FRONTIERS IN MEDICINE, 2020, 7
  • [8] CYTOKINE RELEASE SYNDROME (CRS) AND NEUROTOXICITY IN CAR-T CELL THERAPY PATIENTS
    Delrosario, Maria Regina
    Davison, Lisa
    Schwen, Sarah
    ONCOLOGY NURSING FORUM, 2019, 46 (02)
  • [9] Spotlight on Tocilizumab in the Treatment of CAR-T-Cell-Induced Cytokine Release Syndrome: Clinical Evidence to Date
    Si, Stephanie
    Teachey, David T.
    THERAPEUTICS AND CLINICAL RISK MANAGEMENT, 2020, 16 : 705 - 714
  • [10] Prophylactic tocilizumab to prevent cytokine release syndrome (CRS) with teclistamab: A single-center experience
    Scott, Sara A.
    Marin, Ellen M.
    Maples, Kathryn T.
    Joseph, Nisha S.
    Hofmeister, Craig C.
    Gupta, Vikas A.
    Dhodapkar, Madhav V.
    Kaufman, Jonathan L.
    Lonial, Sagar
    Nooka, Ajay K.
    BLOOD CANCER JOURNAL, 2023, 13 (01)
12345